Alzheimer's disease: from molecular pathogenesis to innovative therapies.
Alzheimer's disease is the most common neurodegenerative disorder and most prevalent cause of dementia in the elderly. Current standard treatment of Alzheimer's disease is based on the use of acetylcholinesterase inhibitors, which have shown symptomatic benefits on cognitive, functional and behavioral symptoms of the disease. A growing body of evidence suggests that the accumulation of amyloid beta-peptides may play a pivotal role in the pathogenesis of Alzheimer's disease (amyloid hypothesis). The incremental progress in elucidating the molecular basis of Alzheimer's disease is pointing the way towards more targeted and pathogenically specific treatment approaches. This review analyzes the available data on the new directions of Alzheimer's disease therapy, with particular focus on secretase inhibitors, amyloid beta-peptide vaccination,anti-inflammatory agents, metal chelators and cholesterol-lowering drugs.
Scarpini
Elio
E
Department of Neurological Sciences, Dino Ferrari Center and Center of Excellence on Neurodegenerative Diseases, University of Milan, IRCCS Ospedale Maggiore Policlinico, via F Sforza 35, 20122 Milan, Italy. elio.scarpini@unimi.it
Cogiamanian
Filippo
F